Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B

Next Previous
Search
Trial Profile

GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidanacogene-elaparvovec (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer; Spark Therapeutics

    • Most Recent Events

    • 12 Dec 2023 Results reporting descriptive data on impact on HRQoL for participants in the fidanacogene elaparvovec phase 1/2a study (NCT02484092) and its LTU study (NCT03307980) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Results assessing Follow-up of More Than 5 Years presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 07 Jan 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top